Clinical Trials Logo

Clinical Trial Summary

The findings of previous experiments suggested that alpha linolenic acid (ALA) has been linked to anti-hyperglycemic, and reducing the risk of diabetes.This is a randomized double-blind cross-over trial, aims to study the effect of ALA on glycemic status and human metabolism. Firstly, the investigators will investigate the efficacy of ALA on improving the indexes of glucose metabolism. Secondly, next generation sequencing (NGS), ultra-high performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) and gas chromatography-mass spectrometry detection will be conducted to explore the role of ALA on gut microbiota as well as metabolites. Thirdly, single nucleotide polymorphism will be genotyped by Time-of-flight mass spectrometry to find the gene-environment interaction effect.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05053347
Study type Interventional
Source Huazhong University of Science and Technology
Contact
Status Not yet recruiting
Phase N/A
Start date February 20, 2022
Completion date December 31, 2022